Insulin Resistance Market Overview
Insulin Resistance Market size is forecast to reach 38.19Bn by 2025, growing at a CAGR of 5.3% during the forecast period 2020-2025. Insulin resistance is a pathological condition in which cells fail to respond normally to the hormone insulin. Increasing prevalence of diabetes and rise in sedentary lifestyle are the major factors driving the growth of the market. Increasing government initiative to increase insulin resistance is set to further enhance the overall market demand of insulin resistance during the forecast period 2020-2025.
The report: “Insulin Resistance Market Forecast (2019-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Insulin Resistance Market.
By Type: Rapid Acting Insulin, Long Acting Insulin, Short Acting Insulin, Intermediate Insulin and Ultra Acting Insulin.
By Drug Class: Biguanides, Corticosteroids, Thiazolidinediones, Insulin, Lipase Inhibitors, Glucagon-like Peptide 1 (GLP-1) Receptor Agonists and Dipeptidyl Peptidase-4 (DPP-4).
By Drug: Branded and Generics
By Diseases: Diabetes, Pre-Diabetes, Metabolic Syndrome, Hypertension, Obesity, Dyslipidemia and Alzheimer’s Disease
By End Users: Home Healthcare, Hospitals, Over the counter, Clinics and Others
By Geography: North America, Europe, Asia Pacific and RoW
- Asia Pacific dominates the Insulin Resistance Market owing to the rising body mass index level and increase in smoking habits among population. The Insulin Resistance Market scope for different regions will be provided in the final report.
- Rising healthcare providers and increasing incidence of diabetes is likely to aid in the market growth of insulin resistance.
- Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Insulin Resistance Market report.
- Availability of limited drugs and lack of information on insulin resistance is set to create hurdles for the Insulin Resistance Market.
Type - Segment Analysis
The Rapid Acting Insulin segment held the largest share in the Insulin Resistance Market in 2019 and is estimated to grow at a CAGR of 3.22% during the forecast period 2020-2025 owing to its usage in insulin pumps to provide a continuous low level of insulin. This continuous flow of basal insulin is the ongoing insulin that is needed to manage normal fluctuations in blood sugar between meals and during sleep. Ultra‐long acting insulin is defined as insulin showing the clinically significant biological action of a glucose lowering effect beyond 24 hours after subcutaneous injection in individuals with diabetes mellitus. Rapid acting insulin is set to be the highest growing segment during the forecast period 2020-2025.
Diseases - Segment Analysis
Diabetes segment held the largest share in the Insulin Resistance Market in 2019 and is estimated to grow at a CAGR of 3.29% during the forecast period 2020-2025. Diabetes is a condition that impairs the body’s ability to process blood glucose also known as blood sugar. Diabetes can lead to a buildup of sugars in the blood, which can increase the risk of dangerous complications, including stroke and heart disease. Different kinds of diabetes can occur and managing the condition depends on the type. Not all forms of diabetes stem from a person being overweight or leading an inactive lifestyle. Dyslipidemia refers to unhealthy levels of one or more kinds of lipid (fat) in your blood. Dyslipidemia is divided up into primary and secondary types. Primary dyslipidemia is inherited. Secondary dyslipidemia is an acquired condition. That means it develops from other causes, such as obesity or diabetes. Diabetes is set to be the fastest growing segment during the forecast period 2020-2025 boosting the growth of the Insulin Resistance Market.
Geography - Segment Analysis
Asia Pacific dominates the insulin resistance market with a share of more than 38%, followed by North America owing to the rising body mass index level and increase in smoking habits among population. Increasing cases of diabetes and other co-morbid disorders is increasing the growth of the insulin resistance market in the Asia Pacific region.
However, North America is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the high body mass index. Sedentary lifestyles rise in diabetes patients and increasing air population is boosting the growth of the insulin resistance market.
Drivers – Insulin Resistance Market
- Rising healthcare providers and increasing incidence of diabetes
Rising healthcare providers and increasing incidence of diabetes is increasing the growth of the insulin resistance market. Insulin resistance is a pathological condition in which cells fail to respond normally to the hormone insulin. Insulin is a hormone that allows glucose to enter cells which also reduces blood glucose (blood sugar). Insulin is released by the pancreas in response to carbohydrates consumed in the diet. In states of insulin resistance, the same amount of insulin does not have the same effect on glucose transport and blood sugar levels. Diabetes occurs when glucose levels become higher as the resistance increases and compensatory insulin secretion fails. Gestational diabetes is diabetes diagnosed for the first-time during pregnancy. Like other types of diabetes, gestational diabetes affects how your cells use sugar. Gestational diabetes causes high blood sugar that can affect pregnancy and baby's health. Thus, boosting the growth of the insulin resistance market.
- Increasing prevalence of diabetes and rise in sedentary lifestyle
Increasing prevalence of diabetes and rise in sedentary lifestyle is increasing the growth of the insulin resistance market. Rise in sedentary lifestyle with aging population and increasing obesity prevalence is poised to give rise to patients suffering from insulin resistance. Adoption of sedentary lifestyle due to and reduced physical activities are adding to worries. The glucose tolerance test is a medical test in which glucose is given and blood samples taken afterward to determine how quickly it is cleared from the blood. The test is usually used to test for diabetes, insulin resistance, impaired beta cell function and sometimes reactive hypoglycemia and acromegaly or rarer disorders of carbohydrate metabolism. Thus, increasing the growth of the insulin resistance market.
Challenges – Insulin Resistance Market
- Availability of limited drugs and lack of information on insulin resistance
Some of the factors that is set to impede the growth of the Insulin Resistance Market are availability of limited drugs and lack of information on insulin resistance.
Insulin Resistance Industry Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the insulin resistance market. In 2019, Insulin Resistance Market share is consolidated by the top ten players present in the market. Insulin resistance, top 10 companies are GlaxoSmithKline Plc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Nova Nordisk, Teva Pharmaceuticals, Sanofi, GlaxoSmithKline, Mylan, Oramed Pharmaceuticals and Takeda Pharmaceuticals.
- In January 2019, GlaxoSmithKline Plc acquires Tesaro.
- In January 2020, Eli Lilly and Company acquires Dermira.
1. Insulin Resistance Market - Overview
1.1 Definitions and Scope
2. Insulin Resistance Market - Executive Summary
2.1 Market Revenue and Key Trends by Company
2.2 Key trends by Type
2.3 Key trends by Drug Class
2.4 Key trends by Drug Type
2.5 Key trends by Diseases
2.6 Key trends by End Users
2.7 Key trends by Geography
3. Insulin Resistance Market – Comparative Analysis
3.1 Product Benchmarking – Key Companies
3.2 Financial Analysis – Key Companies
3.3 Market Value Split by Key Companies
3.4 Patent Analysis – Key Companies
3.5 Pricing Analysis
4. Insulin Resistance Market - Startup Companies Scenario (Premium)
4.1 Key Startup Company Analysis by
4.1.3 Venture Capital and Funding Scenario
5. Insulin Resistance Market – Industry Market Entry Scenario Premium (Premium)
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case Studies of Successful Ventures
6. Insulin Resistance Market Forces
6.1 Market Drivers
6.2 Market Constraints/Challenges
6.3 Porters five force model
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7. Insulin Resistance Market – Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle
8. Insulin Resistance Market – By Type (Market Size –$Million/$Billion)
8.1 Rapid Acting Insulin
8.2 Long Acting Insulin
8.3 Short Acting Insulin
8.4 Intermediate Insulin
8.5 Ultra-Long Acting
9. Insulin Resistance Market – By Drug Class (Market Size –$Million/$Billion)
9.5 Lipase Inhibitors
9.6 Glucagon-like Peptide 1 (GLP-1) Receptor Agonists
9.7 Dipeptidyl Peptidase-4 (DPP-4)
10. Insulin Resistance Market – By Drug (Market Size –$Million/$Billion)
11. Insulin Resistance Market – By Diseases (Market Size –$Million/$Billion)
11.3 Metabolic Syndrome
11.7 Alzheimer’s Disease
12. Insulin Resistance Market – By End Users (Market Size –$Million/$Billion)
12.1 Home Healthcare
12.3 Over the counter
13. Insulin Resistance Market - By Geography
13.1 North America
13.2.6 Rest of Europe
13.3 Asia Pacific
13.3.4 South Korea
13.3.6 New Zealand
13.3.7 Rest of APAC
13.4 Rest of the World
13.4.1 Middle East
13.4.3 South America
14. Insulin Resistance Market - Entropy
15. Insulin Resistance Market – Industry/Segment Competition Landscape (Premium)
15.1 Market Share Analysis
15.1.1 Global Market Share – Key Companies
15.1.2 Market Share by Region – Key companies
15.1.3 Market Share by Countries – Key Companies
15.1.4 Best Practices for Companies
16. Insulin Resistance Market – Key Company List by Country Premium (Premium)
17. Insulin Resistance Market Company Analysis
17.1 Company 1
17.2 Company 2
17.3 Company 3
17.4 Company 4
17.5 Company 5
17.6 Company 6
17.7 Company 7
17.8 Company 8
17.9 Company 9
17.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.